FDA grants validate fast track status

Source: China Council for the promotion of drugs 2014-01-24 on the morning of January 23, 2014, bioalliance pharmaceutical company announced that the U.S Food and Drug Administration (FDA) has granted valid (clonidine lauriad) for the prevention and treatment of radiotherapy and / or chemotherapy for cancer patients with oral mucositis for rapid access Severe oral mucositis induced by intensive radiotherapy and chemotherapy is a highly disabling disease, especially in patients with head and neck tumors In severe cases, it can cause severe oral pain and eating disorders, requiring enteral or parenteral nutrition About 30% of patients have to be hospitalized, which leads to the interruption or delay of anti-cancer treatment and affects the chance of treatment success There are currently no approved therapeutic or preventive drugs Validic (clonidine lauriad) is a kind of oral mucosal adhesive based on lauriad's proprietary technology It releases high concentration of anti-inflammatory active ingredient (clonidine) in the radiotherapy position of head and neck cancer patients Original link: http://www.rttnews.com/2255654/bioalliance-pharma-says-fda-grants-valid-with-fast-track-design.aspx